Index

Note: Page numbers in bold refer to the main sources of information

5-year survival rates, 206
8 methoxypsoralen (8MOP), 138

A
ABCDE guidance formula, 204
ablative methods, 6
abscess, 224
abuse and discrimination, of skin, 3–4
acetyl CoA, 21
aciclovir, 167, 227, 228
acid mantle, 24, 52
acitretin, 135, 140, 141
acne, 18, 26, 29, 39, 54, 88, 179–93
bacterial activity and resulting inflammation, 181–2
with comedones, 181
conglobata, 182–3
with cysts, 182
and distribution, 184
genetics, impact of, 184
infantile acne, 184
middle age, acne in, 184
follicular plugging, 181
fulminans, 182–3
meaning of, 179
pathogenesis, 180
psychological impact, 192–3
rosacea, see rosacea
scarring, 183–4
sebum, production of, 180–81
treatments
general guidance, 185
photodynamic therapy, 192
severe acne, 189–92
topical treatments, 186–9
acquired immune deficiency syndrome (AIDS), 242
acral lentiginous melanoma, 203
actinic keratosis (AK), 196
diagnosis, 197
treatment, 197
actinic LP, 257
active ingredients, 72
active listening, 93
acute dermatitis, 162
acute eczema, 151–2, 157
acute inflammation, 50
acute lesion, 32
acute staphylococcal infections, 224
acute urticaria, 263
adalimumab, 142
adapalene, 186
Addison’s disease, 13
adherence, 110, 243
to therapies, 221
adjuvant treatments, 204
adolescents, 208
adornment, of skin, 3
adrenaline, 263
adrenocorticotropic hormone, 13, 89
adulthood eczema, 160–61
adverse drug reactions (ADRs), 44, 54–5
prevention, 59
advice, 93
aesthetic considerations, of skin health, 5
aesthetic knowledge, 43
Afro-Caribbean hair, 17
Afro-Caribbean skin, 16, 183
ageing, 5, 24
ageing and skin, 24, 27
at birth, 24
old age, 27
post-birth/early months, 25
arterial naevi, 25–6
benign acquired melanocytic lesions, 25
congenital melanocytic naevi, 25
milia, 25
mongolian blue spot, 25
physiological jaundice, 26
vascular naevi, 25
pre-birth, 24
pregnancy, 26–7
puberty, 26
air pressure alleviating mattresses, 57
airborne contact dermatitis, 157
Ajzen’s Theory of Planned Behaviour, 209
albinism, 3, 201
alcohol abuse, 123
alkaline skin, 55
allergen load, 56
allergic, 72
allergens, 20, 163
allergic contact dermatitis, 52, 152, 155, 162–3
allergic reaction, 73
allergy testing, 155
alopecia areata, 233
amelanotic melanoma, 197
amino acids, 12
ammonia, 53
amniotic fluid, 24
anagen, 17
anaphylactic shock, 74, 263
androgener, 26, 179
angioedema, 263
anogenital warts, 232
anoxia, 52
anthralin, see dithranol
antibacterial product, 187, 186
antibacterial therapy, 164
antibiotics, 44, 167
antibiotic therapy, 164, 226
antibodies, 50
anticipatory grief, 207
antifungal drugs, 44
antigen-presenting cells, 14
antihistamine, 46, 164, 264
anti-inflammatory, 262
anti-inflammatory properties of emollients, 81
of retinoids, 186
antimicrobials, 167
antipruritic agents, 82
antiviral agents, 44
antiviral drugs, 44
anxiety, 92, 96, 211
anxiety management, 108
apocrine sweat glands, 19–20
appendageal structures, of skin, 17–20
hair, 17
growth, 17
types, 17–18
nails, 18–19
sebaceous glands, 18
sweat glands, 19
apocrine sweat glands, 19–20
eccrine sweat glands, 19
appendages, of skin, 35
appraisal, 96
aqueous cream, 74
arrector pili muscle, 18
arterial naevi, 25–6
arthritis, 123
arthritus mutilans, 129
assessment, of skin, 29, 30–42, 38
examination, of skin, 35
history taking, 35–7
lesions, understanding and describing, 31
rashes, 32–5
normal skin, 30
body surface area, 30–31
racial variations, 30
nursing diagnoses, 37–8
technological aids, 41–2
tools, 38
disease-related quality of life, 40
severity tools, 38–40
aseastic eczema, 152, 158, 161, 170
atxia, 228
athlete’s foot, 235
atopic dermatitis, see atopic eczema
atopic eczema, 4, 14, 29, 50, 88, 152, 154–157, 158, 222
climate for, 156
clinical signs, 154–5
environmental factors increasing prevalence of, 156
epidemiology, 154
holistic assessment for, 159
significance and impact of, 156–7
treatment, 166–173
bacterial infection, management of, 167
behavioural management, 168
complementary therapies, 169–70
oral immunosuppressant therapies, 169
phototherapy, 168–9
seborrhoeic eczema, managing fungal infections in, 167–8
sedating antihistamines, 168
topical calcineurin inhibitors, 168
viral infection, management of, 167
trigger factors, 155–6
atrophic cicatrical alopecia, 256
atrophic macular scars, 183
atrophic scars, 183
atrophied skin, 12
atrophy, 24, 32
attachment styles, 112
attachment theory, 112
attitudes, 61
and behavioural change, 208
audiovisual materials, 106
Auspitz sign, 122
autoantibodies, 264
autoimmune nervous system, 89
autoregulatory systems, 52
axillary hair, 26
azathioprine, 143, 169
azelaic acid, 187, 261-2
bacterial infection, managing, 167
bacterial resistance, 167
risk factors, 188
bacterial skin infections, 221
cellulitis and erysipelas, 225–6
folliculitis and related conditions, 224
impetigo, 224–5
staphylococcal scalded skin syndrome, 224–5
bacterial swab, 223
bactericial effect, 187
bacteriology, 46
bad hair day, 24
BAD Therapy Guidelines and Audit Committee, 173
bald patches, 92
bandages, 44
bandaging techniques, 56–7
Bandura’s Self-efficacy Construct, 61
barrier cream, 55
barrier dysfunction, 80
barrier function, of skin, 20, 49, 72, 90, 153
chemical protection, 20
immunological surveillance, 20–21
physical protection, 20
basal cell carcinoma (BCC), 27, 198
clinical presentations, 199
definition, 198
high- and low-risk BCCs, 198–9
prevention, 200–201
treatment, 200
types, 198
basal lamina, 14
basal layer, 12–13
basalioma, 198
basement membrane zone, 14–15
basisquamous BCC, 199
Bateman, Thomas, 121
bath additives, 75
bath oils, 167
BCC, see basal cell carcinoma
BDNG (British Dermatological Nursing Group), 57
beauty industry, 5
beauty treatments, 5
Beck Anxiety Inventory, 97
behaviour change, 60, 95, 209
behavioural management, 63–4, 171
beliefs, 61
benign acquired melanocytic lesions, 25
benign melanocytic naevi, 41
benign tumours, 29
benzoyl peroxide (BPO), 186, 187
benzylkonium chloride, 82
beta-blockers, 131
betamethasone valerate, 165
Index 275

bevacizumab (AVAST-M), 204
bilirubin, 26
biochemical reactions, in skin, 23
biofeedback, 172
biologic drugs, 141–3
potential side effects of, 145
and prescribing regimes, 142
biologic monitoring, 45
biological barriers, 88
biological therapy, 44, 124
biology, of skin, 11–28
ageing and skin, 24–7
functions, of skin, 20–24
structure, of skin, 11–20
biopsy, 41–2, 44, 208, 250
black eschar, 52
blackheads, 181
bleaching creams, 183
bleeding, 86
blepharitis, 261
blistering conditions, in skin, 29, 247
epidermolysis bullosa, 248–9
immunobullous diseases, 249–51
blood cultures, 223
blood pressure, 250
blood vessels, 16
body image, 87
body language, 93
body lice, 241
body map, 30
body odour, 20
body surface area (BSA), of normal skin, 30–31
boils, 224
bonding, 22
bony prominences, 57
Borders’ classification system, 201
Botox, 6
botulinum toxin, 6
Bowen’s disease, 196, 197
Bradens Scale, 58
bradykinin, 50
brain–skin axis, 85, 131
breakdown of skin, causes of, 50–55
dry skin, 50–51
inflammation, 50
poor perfusion and disrupted microcirculation, 51–2
skin breakdown, factors affecting, 54–5
urine and incontinence, effects of, 53–4
washing (skin hygiene) practices, effects of, 52–3
breast feeding, 156, 249
breathing exercises, 59
Breslow thickness, 202
brick wall, 80
British Association of Dermatologists, 141, 168
British Association of Dermatologists Diagnostic Index, 29
British Dermatological Nursing Group, 113
British National Formulary (BNF), 113, 134, 164
British National Health Service, 3
brown fat, 21
bullae, 32, 34, 160, 162, 223
bullous impetigo, 223
bullous LP, 257
bullous pemphigoid, 15, 247, 249
burning, of skin, 60
burrows, 240
C
C fibres, 22
cadherins, 13
calcineurin inhibitors, 262, 266
calcipotriol, 135
and betamethasone dipropionate, 134–5
calcitriol, 132
calcium, 23
camouflage, 208, 266
camouflage techniques, 183–4
Cancer Help, 207
cancer, in skin, see skin cancer
Cancerbacup, 207
Candida, 237
Candida albicans, 238, 239
candidiasis, 41
CAP fluoroimmunoassay tests, 264
carbohydrate, 62
carboxylic gelling agent, 76
carbon dioxide laser, 200
carbuncles, 224
carcinogenic substances, 135
cardiovascular disease, 51
care consultation, 110
catagen, 17
catecholamines, 89
Caucasian hair, 17
Caucasian skin, 16
cautery, 44, 200, 201, 262
cell-mediated immune response, 123, 254, 255
cellulitis, 44, 223, 225, 226
cellulitis erysipelas, 51
Centella asiatica, 27
ceramides, 14
ceruminous glands, 20
cetostearyl alcohol, 72
cellular immunity, 53
chemical peels/dermabrasion, 184
chemical protection, of skin, 20
chemotherapy, 202
chest X-ray, 143
chickenpox, see varicella zoster
childhood eczema, 160
childhood sun exposure, 208
Children’s Dermatology Life Quality Index (CDLQI), 99, 159
chiropractors/podiatrists, 114
chloasma, 26
chloasma pigment, 26
chlorhexidine hydrochloride, 82
chloroquine-based anti-malarials, 131
cholesterol, 14
cholinergic urticaria, 264
chronic actinic dermatitis, 157
chronic dermatitis, 158
chronic disease management, 104, 172
chronic eczema, 152, 158
chronic illness management, 103–4
chronic irritant eczema, 158
chronic lesions, 32
chronic oedema, 51
chronic plaque psoriasis (CPP), 124–5
chronic skin severity tools, 39–40
chronic urticaria, 264
ciclosporin, 140, 169
classical conditioning, 63
cleansers, 52, 55, 75–6
clindamycin, 187
clinical decision-making, concepts and theories of, 43–4
clinical images, 8
Clinical Knowledge Summaries (CKS), 114
clinical management plan (CMP), 114
clinical nurse specialist, role of, 206
clinical psychologist, 92, 207
clinical severity, of skin assessment, 38
clobetasol propionate, 250
clonidine, 262
closed comedones, 181
clotrimazole, 236
clothed nails, 35
cocaine, 135
method of application, 135–6
cocoamido-propyl betaine, 52
cognitive behavioural approaches, 63
cognitive behavioural therapy, 93
cold sores, 223
collagen, 16, 15
synthesis, 62
colonisation, of skin, 52
colour, of skin, 29, 32
combing, 242
comedones, 26, 181
commensal bacteria, 24
commensal organisms, 20, 238
common skin disorders, classic lesion distribution in, 36
cryotherapy, 197, 200, 201, 230, 232
cryoscite cream, 230
CTCL, see cutaneous T-cell lymphomas
cultural influences, of skin, 2
curettage, 44, 200, 201, 232
cutaneous itch, 22
cutaneous lymphatics, 16
cutaneous melanomas, 202
cutaneous T-cell lymphomas (CTCL), 54, 201
mycosis fungoides, 201
primary cutaneous CD30+
lymphoproliferative disorders, 202
Sézary syndrome, 202
treatment, 202

cuticle, 18
cysteine, 12
cystic lesions, 182
cytokines, 20, 22, 123, 154
production, 90
cytoplasm, 12
cytotoxic agents, 45

dactylis, 129
daughter cells, 12
debris, 75
decision-making, 110
decoration, of skin, 3
deep breathing exercises, 96
dehydration, 21, 228
delusional parasitosis, 92
Demodex folliculorum, 261
dendritic cells, 14
Department of Health (DH) website, 114
depression, 86, 96
dermabrasion, 184
dermal necrosis, 52
dermal papilla, 15, 18
dermatitis, 151
dermatitis artefacta, 92
Dermatitis Family Impact
Questionnaire, 38, 159
dermatitis, see eczema
dermatological diagnoses, 29, 43
dermatological emergency, 127
dermatological ‘red flag’ conditions, 44
dermatology consultation, 111
Dermatology Life Quality Index
(DLQI), 98
dermatomal distribution, 228
dermatomes, 229
dermatomyositis, 251
dermatophyte infections, 41, 233
dermatoscope, 41, 198
dermis, 15–16
dermographism, 264
dermoscope, see dermatoscope
descaling agents, 82
desmoglein, 224
desmosomes, 13
desquamation, 12, 54, 60, 80
detergents, 164
developmental stage, 35
of child, 171
diathermy, 262
diclofenac gel, 197
diet, 156
direct immunofluorescence, 250
disability, 97
and impairment, 86–7
discoid eczema, 151, 158,
160, 170
discomfort, 91
discrimination, 3, 88
disease, typology of, 90
disease severity, 97, 157
display, of skin, 3
disseminated herpes simplex, 227
disseminated herpes zoster, 229
distal and lateral subungal
onychomycosis (DLSO), 236
distal interphalangeal joint arthritis, 129
dithranol, 44, 132, 136
method of application, 136
doctor/patient relationship, 222
doxycycline, 188
dressings, 44, 249
drug administration, 112–13
drug hypersensitivity syndrome, 253
drug induced dry skin, 50
drug reactions, 252–3
drug hypersensitivity syndrome, 253
drug-induced photosensitization,
254, 255
drug-induced skin pigmentation,
253–4
fixed drug reactions, 253
toxic erythema, 253
dry skin, 50–51, 54
dry wraps, 56
drying, 55, 236, 238
drying practices, 55
dryness, problem of, 59
dystrophic type of EB, 248
dysuria, 227

E
EB simplex, 248
eccrine sweat, 21
eccrine sweat glands, 19
economic pressures, 87
ectoderm, 24
eczema, 29, 78, 90, 110, 151–73
adulthood eczema, 160–61
atopic eczema
clinical features and epidemiology, 154–7
behavioural treatments, 170
caring for children with, 159–60
childhood eczema, 160
classification, 152
contact dermatitis, 161–3
diagnosis, 157–8
differential diagnoses, 157–8, 173
economic cost, 156
meaning of, 151–3
biology and pathophysiology of, 153–4
severity assessment, 158–9
for treating eczema, 170, 171
educational resources, 105
awareness of, 105–7
efalizumab, 141
efficacy, 72
elastic fibres, 16
elasticity, of skin, 35, 60
elastin, 15
elephantiasis, 5
Elidel®, 168
elliptical biopsy, 259
embryogenesis, 24
emetophobia, 92
emollients, 56, 71–83, 132
antimitotic properties, 81
antipruritic properties, 81
cosmetics, 72–3
definition, 71–2
of eczema, 164
formulations, 75
bath additives, 75
leave-on topical emollients, 76–80
skin cleansers, 75–6
how to apply, 77–8
potential side effects, 73
contact dermatitis, 73–4

occlusive nature, adverse effects caused by, 74–5
safety concerns, 75
therapy, 55–6, 164
usage, factors affecting, 82–3
when to apply, 78–9
where to apply, 79–80
working mechanism, 80–82
emotional behaviour, regulation of, 108–9
emotional importance, of skin, 1
emotional involvement, 111
emotional response, 206
empathy, 111
empirical knowledge, 42–3
emulsifiers, 76
emulsifying wax, 72
emulsion, 72, 76
encephalitis, 228
endogenous eczema, 151
endobothrix infection, 237
endoplasmic reticulum, 12
endothrix infection, 233
energy storage, 21
entonox, 249
environmental changes, affecting skin, 4
epidermal necrosis, 52
epidermal proliferation, 90
epidermis, 11–12
basal layer, 12–13
granular layer, 14
horny layer, 14
prickle cell layer, 13–14
epidermolysis bullosa, 15, 44, 248
autosomal dominant forms of, 248
autosomal recessive forms of, 248
Epidermophyton, 233
Epidermophyton floccosum, 235
eponychium, of nail, 19
erosion, 32
erethia, 30, 39
erythema, 30, 39
erythema multiforme, 54, 227
erythema nodosum, 54
erythemalocorticicatos rosacea, 260
erythenomatous skin, 32
erythrasma, 41
erythrodema, 54
erythrodemic psoriasis (EP), 44, 127
erythromycin, 187, 188
essential fatty acids (EFAs), 62
etanercept, 142
ethnic differences, in skin structure, 16
European Medicines Agency, 141
European Pressure Ulcer Advisory Panel (EPUAP), 52
European standard battery, 163

European Task Force on Atopic Dermatitis, 39
evaporation, 21, 32
examination, of skin, 35
excipients, 72
excision, 44
excisional biopsies, 42
excoriated lesion, 32
excoriation, 32, 241
exfoliation, 6
exfoliative dermatitis, 54
exocytosis, 14
exogenous eczema, 151
exothrix infection, 233
extrinsic ageing, 27

F
facial flushing, 260
faecal incontinence, 53
faeces, 53
famciclovir, 227, 229
fast pain, 23
fats, 72
fatty acids, 14
fauna, 24
feet, 235
female genital mutilation, 3
fibrin, 50
fibroblasts, 15
fibrosis, 51
filaggrin, 14
filaggrin mutations, 153
filiform warts, 232
fillers, 6
fine touch, 22
finger nails, 236
Finger Tip Unit (FTU), 166
finger/toenail, 237
fingerprint, 16
Finn chambers, 42, 163
fissures, 32, 53, 50, 160
fixed drug reactions, 253
flammability, 75
flare-ups, 166
flat lesion, 32
flax, 222
flexural areas, 154
flexural dermatitis, 154
flexures, 125
flora, 24
fluid-filled lesion, 32
fluorouracil, 197
foetus, 27
fold, of skin, 238
follicle, 181
follicular keratinocytes, 180
follicular macular atrophy, 183
follicular plugging, 180, 181
follicular pustules, 224
folliculitis, 74, 135, 224, 242
foot and nail care, 238
foot hygiene, 236
footwear, 236
free nerve endings, 22
friction, 53, 58
friction coefficient, 53
frictional damage, 55
fumarates, 143
fumaric acid esters, 143
functions, of skin, 20
barrier function, 20–21
biochemical reactions, in skin, 23
heat loss, 21
psychosocial, 23–4
sensation, 21–3
storage, 21
temperature regulation, 21
fungus, 221, 223, 233
dermatophyte (ringworm) infections, 233–8
pityriasis versicolor, 239–40
in seborrhoeic eczema, 167–8
yeast infections, 238–9
furuncle, 224
fusidic acid, 224
gabapentin, 229
gangrene, 24
gastrostomy, 249
gel emollients, 76–7
generalised pustular psoriasis (GPP), 126, 127
genes, 121
genetic counsellor, 249
genetics, 27
impact of, 184
genital erosive LP, 257
genital thrush, 238
genital warts, 231
genuine, being, 111
germs, 24
gingivostomatitis, 226
glabrous skin, 17
glomerulonephritis, 240
glucose, 250
glycerine, 81
glycol, 72
glycoproteins, 13
glycosaminoglycans (GAGs), 15
Goeckerman regime, 135
Golgi complex, 12
grafting, of skin, 44
granular layer, 14
gravitational eczema, see varicose eczema
griseofulvin, 234, 237
ground substance, 15
group support, 106
guilt, 86
vestatory sweating, 19
guttate psoriasis (GP), 125–6, 223
habit reversal, 63
haemorrhagic blisters, 250
haemosiderin, 35
hair, 2, 17, 35, 41
debits, 234
ethnic groups, 17
follicle, 17, 22, 26
growth, 17
shaft, 18
structure of, 18
types, 17–18
hair-root plexuses, 22
hand, foot and mouth disease, 232
hand protection, 238
hand washing, 161, 222, 223
handicap, 87
head lice, 242
infestations, 242
health behaviour, 104
Health Care Commission, 3
health education, 30, 61
health/patient education, 172
health promotion, 109
healthy skin, 1, 2
heat loss, from skin
conduction, 21
convection, 21
evaporation, 21
radiation, 21
hemidesmosomes, 14, 15
hepatitis, 228
herald patch, 257
herpes encephalitis, 227
herpes infections, 223
herpes simplex, 44, 167, 226, 242
herpes simplex virus (HSV), 88, 226–7
herpes zoster, 44, 228, 242
herpetic whitlow, 227
heuristics, 43
histamine, 16, 22, 50, 262
histocytes, 16
history taking, 35–7
HIV, 237, 242
infection, 4, 230, 240
Holt, L.E, 22
home environment, 156
hormonal therapies, 189
horny layer, 14
house dust mites, 155, 156
human genome, 121
human immunodeficiency virus (HIV), 222, 253
human papilloma virus, 231
humectant, 72, 80, 81
humid environments, 238
hyaluronic acid, 15, 60
hydration, of skin, 55, 56
promotion, 55–7
hydrocoele, 4
hydrocortisone, 165
hydroxyurea, 143
hygiene, 52, 238
hypothesis, 4, 153
self-care, 37
hyperaemia, 50
hyperkeratinisation, 180
hyperkeratosis, 51, 122
hyperkeratotic lesion, 32
hyperpigmentation, 16, 61
hyperplasia, 24
hyperproliferation, 21, 122
hypersensitivity reactions, 42
hypertrichosis, 165
hypertrophic LP, 256
hypertrophic scars, 183
hypertrophy, 24
hypnotherapy, 172
hypochromia, of nail, 19
hypothalamic–pituitary–adrenal axis, 88
hypothalamus, 21
hypothetico-deductive theory, 43
iatrogenic effects, 54
ice-pick scars, 183
ichthyoses (inherited), 50
icterus neonatorum, see physiological jaundice
ichthyosis, 14
id response, 233
IgE-mediated response, 74
IL-1α, 81
Imiquimod, 197, 200, 230
immune system, 1, 153
immune-mediated response, 74
immunity, 20–21
immunocompromised patients, 228
immunodeficiency, 224
immunoglobulin (Ig) E, 153
immunological surveillance, of skin, 20–21
immunomodulators, 164
immunosuppressed patients, 238
immunosuppression, 169, 240, 250
immunosuppressive agents, 44
impaired skin integrity, risk for, 38
impairment, 86, 87
impetigo, 221, 222–4
impetigo contagiosa, 222
incisional biopsies, 42, 44
incontinence, 55, 58
assessment and limiting effects of, 58–9
independent prescribing, 113–14
Indo-Chinese hair, 17
induration, 39
due to hyperkeratosis, 122
of plaque, 129
infantile acne, 184
infantile seborrhoeic dermatitis, see cradle cap
infantile seborrhoeic eczema, 156
infants, 156
Infants Dermatology Life Quality Index, 159
infections, of skin, 221
infective disorders, 29
infective skin conditions, 221–43
bacterial skin infections, see bacterial skin infections
fungal infections, see fungal infections
viral infections, see viral infections
infestations, 221, 240–42
lice, see lice
pubic lice, 242
scabies, 240–41
diagnosis, 241
management, 241
inflammation, 21, 50, 56, 130
and skin breakdown, 50
inflammatory acne, 185
inflammatory agents, 81
inflammatory changes, in skin, 35
inflammatory episodes, 59
inflammatory lesions, 187
inflammatory mediators, 164
inflammatory process, 50
inflammatory response, 50, 154
infliximab, 45, 142
information leaflets, 105
information sources, 105
inherited blistering disorders, 248
innate defence system, 20
innate nonspecific resistance, 20–21
insole, 131
insect, 240
insect bites, 44, 222
insensible water loss, 19
integrity, of skin, 37
maintenance, 57–60
intense pulsed light, 262
interferon levels, 153
interferons, 202
interleukin levels, 153
interleukins, 20
International Classification for Nursing Practice (ICN®, 37
International Classification of Disease, 29
International Council of Nurses (ICN), 37
intertrigo, 78, 239
keratin, 12, 14, 52
keratinocytes, 12, 122
keratohyalin, 13, 14
keratolytic agents, 44
kerion, 233, 234
keratocidazole shampoo, 235
keratoacanthoma, 167
kinin, 23
knowledge of self, see personal knowledge
knowledge, types of, 42
Krebs cycle, 21
kwashiorkor, 61
Kawasaki disease, 232–3
keloid scars, 16, 183
steroid injections for, 184
keratin, 12, 14, 52
keratinocytes, 12, 122
keratohyalin, 13, 14
keratolytic agents, 44
kerion, 233, 234
ketacnoazole shampoo, 235
ketacnoazole, 167
Koebner phenomenon, 130
Krebs cycle, 21
Kwashiorkor, 61
keratin, 12, 14, 52
keratinocytes, 12, 122
keratohyalin, 13, 14
keratolytic agents, 44
kerions, 233, 234
ketacnoazole shampoo, 235
ketacnoazole, 167
kinins, 23
knowledge of self, see personal knowledge
knowledge, types of, 42
L
lactic acid, 14
lamellar bodies, 90
lamellated corpuscles, 22
lamina lucida, 14, 248
laminin, 14
Langerhans cells, 12, 14, 20, 153
lanolin, 71, 72
lanugo hairs, 17, 24
laser resurfacing, 6
laser therapy, 44, 192
lasers, 44, 184
lauromacrogols, 82
leave-on topical emollients, 76–80
leg oedema, 226
leg ulceration, 29
leg ulcers, 226
lentigo, 25
lentigo maligna melanoma, 203
leprosy, 23, 50, 121
leukoplakia, 239
leukotrienes, 264
lice, 222, 241–2
lichen planus (LP), 88, 237, 255
actinic LP, 257
bullous LP, 257
classic presentation, 256
erosive LP, 256–7
hypertrophic LP, 256
lichen planus (LP), 88, 237, 255
actinic LP, 257
bullous LP, 257
classic presentation, 256
erosive LP, 256–7
hypertrophic LP, 256
lichen simplex, 160, 170
lichenification, 32, 39, 152, 153, 241
lifestyle, 208
lifestyle choice, 123
lightening, of skin, 3
limb elevation, 59
lipid bilayer, 14
lipid lamellae, 153
lipids, 14, 53, 72
liquefaction, 255
listening, 110, 207
lithium, 131
liver function tests (LFTs), 190
local skin reactions, 200
locus of control, 108
long-term condition, 103
people with, 104
lotions, 76
low self-esteem, 103
lunule, 18, 19
lupus erythematosus-type reaction, 188
lumicelaine, 188
lymph flow, 59
lymph nodes, 205, 212
metastasis, 206
lymphadenectomy, 204
lymphadenopathy, 205, 233
lymphangiectasia, 51
lymphangioma, 51
lymphangitis, 223
lymphatic filariasis, 4, 5, 59
lymphatic impairment, 51
lymphatic vessels papillomatosis, 51
lymphocyte, 123
trafficking, 90
lymphocytosis, 90
lymphoedema, 4, 51, 226
management, 59
services, 208
lymphomas, 201, 258
lymphomatoid papulosis, 202
lymphorrhoea, 51
lysosomal activity, 14
lysosomes, 14

M
maceration, 53
Macmillan Cancer Support, 207
macrophages, 16
macule, 34
major histocompatibility complex
molecules, 14
Malassezia, 167
Malassezia furfur, 160
malignant melanomas, 25, 27
malignant skin cancers, 3
malnutrition, 62
mammary glands, 20
Marc's Line, 207
masking fragrances, 74
mast cells, 263
mattresses, 58
maturity of skin, 51
measurements of skin barrier function,
55
mechanical barrier, 56
medicated paste bandages, 56–7
medication, managing, 105
Medicines and Health care products
Regulatory Agency (MHRA), 114
medicines education, 112
skin-related products and
opportunities for, 112–13
independent prescribing, 113–14
patient group directions, 113
patient-specific direction, 113
supplementary prescribing,
114–15
medulla, 18
Meissner's corpuscles, 16, 22
melanin, 13, 20, 23, 30, 35, 202
melanocyte stimulating hormone
(MSH), 13
melanocytes, 12, 13, 25, 265
melanoma, 41, 195, 202
ABCD guidance formula, 204
adjuvant treatment, 204
diagnosis, psychological impact of,
206–7
distribution, 203
follow-up, 204–5
incidence, 196
metastatic melanoma, 205
prevalence, 196
primary melanoma
diagnosis, 203–4
treatment, 204
risk factors, 203
survival, 205–6
type, 203
melanoma staging system, 205
melanonychia, 256
melanosomes, 13, 30
menstrual cycle, 26
mental health problems, 23
mental health well-being, 91
mental well-being, 85
Merkel discs, see Type I receptors
Merkell cells, 13
mesoderm, 24
metabolic syndrome, 124
metastatic BCC, 198
metastatic disease, 205
self-examination teaching for, 212
teaching of self-examination for, 212
metastases, of skin, 205
metastatic melanoma, 205
methicillin resistant staphylococcus
aureus (MRSA), 223, 224
methotrexate, 45, 139–40
microcirculation, 35
microcomedone, 180
microdermabrasion, 6
microscopy, 41, 223
microsphere, 186
Microsporum, 233
Microsporum audouinii, 41
Microsporum canis, 41, 235
middle age, acne in, 184
mild to moderate acne, 186
azelaic acid, 187
benzoyl peroxide (BPO), 187
nicotinamide, 187
retinoid product, application of,
186–7
topical antibiotics, 187–8
topical retinoids, 186
milia, 25
Milroy's disease, 51
mind, 85
mindfulness-based stress reduction
techniques, 109
minerals, 62
minimal erythema dose, 45, 138
minocycline, 188
mite allergens, 156
mites, 222
mitochondria, 12
mitosis, 18
moderate acne, 188
hormonal therapies, 189
oral antibiotics, 188–9
moisture, 78
moisturisers, 71–2
moisturising, 238
moles, 41
mollusca, 242
molluscum contagiosum, 167, 230
mongolian blue spot, 25
monocyte, 90
monotherapy, 187
morality, 86
morbilliform, 253
morphea, 251
morphoeic BCC, 199
motivation, 103
motivational training, 64
mucous membranes, 250
multidisciplinary approach, for atopic
eczema, 164
mycology, 41
mycosis fungoides (MF), 54, 201, 258,
259–60
myelinated A fibres, 23

N
nail, 2, 17, 18–19, 35, 41, 224
anatomy, 19
structure, 19
nail bed, 19
nail, body of, 19
nail fold, 19
nail, free edge of, 19
nail infections, 35
nail involvement, 128
nail matrix, 18, 19
nail plate, 18, 19, 236
nail psoriasis, 126
narrowband UVB, 169
National Cancer Plan, 204
National Eczema Society, 108, 169,
173
National Institute for Health and
Clinical Excellence (NICE), 143
National Pressure Ulcer Advisory Panel
(NPUAP), 57
natural moisturising factor (NMF), 14,
81, 153
necrosis, 24
negotiation, 110
neonatal bullous impetigo, 223
neonates, 227
neoplasia, 24
nerve growth factor, 89
neurodermatitis, see lichen simplex
neuropeptides, 22
newborn, 24
nicotinamide, 187
nociceptors, 23
nodular BCC, 199
nodular lesions, 182
nodular melanoma, 203
odule, 32, 35, 190, 205
formation, 26
non-ablative methods, 6
non-accidental injury, 25
non-blanchable oedema, 59
non-bullous impetigo, 222
non-comodogenic products, 185
non-erythematous skin, 32
non-immune-mediated reaction, 74
non-inflammatory acne, 185
non-inflammatory lesions, 187
non-malignant skin cancers, 3
non-medical prescribing, 115
non-medical prescribing, information
sources on, 114–15
non-melanoma skin cancer (NMSC), 195
non-melanoma skin lesions, 195
basal cell carcinoma, 198–201
squamous cell carcinoma, 201
normal skin, 30
body surface area (BSA), 30–31
racial variations, 30
North American Nursing Diagnosis
Association (NANDA), 37
nucleus, 12
nurse-independent prescribing, 113, 114
nurse-led dermatology services, 173
nurse-led prevention, 61
nurse-led services, 173
nurse–patient relationship, 111–12
nurse–prescriber–patient consultations, 111
nursing diagnoses, 37–8
nursing intervention, 92, 209
active listening, 93–5
cognitive behavioural therapy, 95–7
skin disease impacts, measurement of, 97–100
to support behavioural change, 60–61
nutritional support to skin integrity, 61–3

O
obesity, 53, 62, 226, 238
obsessive/compulsive disorder, 96
occlusion, 52, 57, 72
occlusive bandages, 79
occlusive body bandages, 166
ocular rosacea, 261
occupational dermatoses, 161
oedema, 26, 39, 51
oils, 72
ointments, 76
oligoarticular arthritis, asymmetric, 129
onycholysis, 126, 254
onychomycosis, 236, 238
open comedones, 181
optometrists, 114
oral antibiotics, 188–9
oral fluconazole, 239
oral immunosuppressant therapies, 169
oral retinoids, 202
osteolysis, 129
over-hydrated skin, 54
over-washing, 50
ovulation, 26
ovulation, 26
oxytetracycline, 188
 ozone protection, 4
P
pain, 22, 23, 130
and pruritus, 130
relief, 249
palmar plantar pustulosis (PPP), 126
palmar psoriasis, 125
palmoplantar psoriasis, 123
palmoplantar pustulosis, 158
palpation, 32, 35
palpillary layer, 16
papillomatosis, 51
papular lesions, 188
papules, 32, 34, 182
papulopustular rosacea, 260
parasites, 222
parasympathetic nervous system, 89
parental education, 157
parental self-efficacy, 108
paronychia, 35
PASI score, 45
paste bandages, 57
patch testing, 42, 74, 162–3
patches, 32
pathogenic microorganisms, 52
pathogens, 1, 20, 221
patient education, 43, 111
patient group directions (PGD), 113
patient history, 35
patient involvement, 111
patient-orientated eczema measure, 158–9
patient participation, 111
patient repositioning, 57
patient-specific direction (PSD), 113
patient support, 103
patient teaching, 172
peanut allergy, 190
pediculicide, 242
peeling, 54
peels, 7
pellagra, 61
pemphigus vulgaris, 88, 251
Penn State Worry Questionnaire, 97
perceived self-efficacy, 108
perfumes, 74
perineal dermatitis, 53
periordial dermatitis, 165
periortial cellinates, 226
peripheral nervous system, 88
permethrin, 241
personal accomplishment, 108
personal knowledge, 43
petrolatum, 72
PH level, 55
pharmaceutical industry, 82
pharmacist-independent prescribing, 113, 114
pharmacists, 114
phosphorous, 23
photo-ageing, 27
photo allergic dermatitis, 163
photoreal allergic sensitisation, 254
photochemotherapy, 169
photodynamic therapy (PDT), 44, 192, 197, 200
photo-patch testing, 163
photopheresis, 202
photosensitisation, 254
photosensitising agent, 162
photosensitivity, 54, 157, 186
phototherapy, 44, 50, 137, 168–9, 202
assessment, 45
and oral immunosuppressants, 168
phototoxic reactions, 162, 254
phymatous rosacea, 261
physical examination, 205
physical protection, of skin, 20
physical urticaria, 264
physiological jaundice, 26
physiotherapists, 114
physiotherapy, 249
piercing, 3
pigment, of skin, 3
pigmentation, of skin, 30
pigmented BCC, 199
pilosebaceous gland, 179
pimecrolimus (Elidel®), 168
pituitary gland, 13, 89
pityriasis rosea, 257–8
pityriasis versicolor, 41, 239
Pityrosporum orbiculare, 239
Pityrosporum ovale, 160
pityrosporum yeast, 41
plane warts, 231
planning care, 42–4
clinical decision-making, concepts
and theories of, 43–4
planning care (cont’d)
clinical judgements, 42–3
dermatological ‘red flag’ conditions, 44
evaluation, 45
intervention, 44–5
plantar psoriasis, 125
plantar warts, 231
plaque, 13, 34
plucking, 17
pneumonia, 228
podiatrist, 238
podophyllotoxin cream, 230
polysaccharides, 15
polysiloxane, 72
pompholyx (pompholyx eczema), 158, 160–61, 170, 171
poor nutrition, 51
poor perfusion, 50
and disrupted microcirculation, 51–2
port wine stains’, 25
positioning, 58
postherpetic neuralgia, 229
post-inflammatory pigmented lesions, 183
post-traumatic stress disorders, 96
potassium, 23
potassium permanganate solution, 226
potency, 165
poverty, 4
skin diseases of, 4–5
pox virus, 230
practical demonstrations, 171
practitioner–patient relationship, 111
prednisolone, 250
pregnancy, 26
pregnant women, 228
pre-malignant skin lesions, 195
actinic keratosis, 196
treatment, 197
Bowen’s disease, 196, 197
diagnosis, 197
prevention, 198
prescriptions, 88, 112
preservatives, 74, 76
pressure, 51
alleviating, 57
effects, 50, 51–2
sores, 53
pressure-relieving beds, 57
PRESSURE trial, 57–8
pressure ulcer, 52
aetiology, 52
prevention, 57, 58
prickle cell layer, 13–14
Primary Care Dermatology Society (PCDS), 168
primary cutaneous CD30+ lymphoproliferative disorders, 202
primary cutaneous lymphomas, 258
primary cutaneous T-cell lymphomas, 258
primary impetigo, 222
primary irritant contact dermatitis, 152
primary lesions, 32
primary melanoma, diagnosis of, 203
primary T-cell lymphomas, 201
printed materials, 106
prodomal phase, 226
professional support, 104
progesterone levels, 26
progressive disease, 90
progressive muscle relaxation, 96
prolactin, 89
propellants, 76
Propionibacterium acnes, 52, 180
colonisation by, 185
propylene glycol, 52
prostaglandins, 22
Protection Motivation Theory, 109
protection, of skin, 49–64
breakdown, causes of, 50–55
damage by scratching, preventing, 63–4
nursing intervention, to support
behavioural change, 60–61
nutrition to support skin integrity, 61–3
preventative practices, 55
promoting skin hydration, 55–7
skin integrity, maintaining, 57–60
skin washing and drying, 55
vulnerability, 49
protein, 15
malnutrition, 61
proximal subungal onychomycosis (PSO), 237
pruritic skin, 57
pruritus, 40, 130
psoriasis, 29, 50, 79, 86, 88, 90, 110, 121–47, 237
biology, 122–3
clinical variants
chronic plaque psoriasis, 124–5
erythrodermic psoriasis, 127
guttate psoriasis, 125–6
nail psoriasis, 126
psoriatic arthritis, 127–8
pustular psoriasis, 126–7
comorbidities associated with, 123–4
differential diagnoses for, 128
history, 121–2
physical symptoms, 128
inflammation, 130
pain and pruritus, 130
scaling, 128–30
proportions of populations having, 122
quality of life, measurement of, 145
service provision, 143–5
systemic drugs for, 143
treatments for, 131
systemic therapies, see systemic therapies, for psoriasis
topical therapies, see topical therapies, for psoriasis
trigger factors in, 130
drugs, 131
koebner phenomenon, 130
streptococcal throat infection, 131
stress, 131
ultraviolet light exposure, 131
Psoriasis Area Severity Index (PASI), 31, 99, 135
Psoriasis Association, 108
Psoriasis Disability Index, 86
psoriasis vulgaris, 124
psoriatic arthritis (PSA), 123, 127–8
clinical presentations of, 129
psoriatic arthropathy, 104
psychological aspects, of skin care, 85, 88–92
brain–skin axis, 88–90
coping, 90–91
mental health well-being, 91–2
psychological assessment, of skin, 38
psychological functions, for healthy
skin, 2
psychological impacts
of acne, 192–3
of chronic skin conditions, 40
of skin disease, 2, 85
psychological importance, of skin, 1
psychological interventions, for treating
eczema, 170
psychological stress, 131
psychological support, 103
psychological well-being, of skin
health, 5
psychorheology, 82
psychosocial impact, of skin disease, 38
psychosocial phases, 207
psychosocial well-being, for atopic
eczema, 159
puberty, 26
pubic hair, 26
pubic lice, 242
pulsed laser therapy, 44
pump dispensers, 79
punch biopsies, 42, 44, 198, 201
purpura, 61
purpuric eruptions, 54
purpuric rash, 44
pustular psoriasis, 126–7
pustules, 32, 182, 186
PUVA, 138–9, 169, 266
pyrrolidonecarboxylic acid, 14

Q
quality of life, 30, 97, 104
impact of skin, 40
measurement, 145
skin disease, impact of, 157
quantities of emollients, 77
quasi-continuous wave laser therapy, 44

R
racial variations, 30
racism, 3
radiation, 21
radiographers, 114
radiotherapy, 54, 59, 200, 201, 202
raised lesion, 32
rashes, 30, 32–5
diagnosis of, 32
reactive hyperaemia, 52
reasoning, 43
red blood cells, 26
red flag conditions, 42, 44
red man syndrome (Sezary syndrome), 202
re-epithelisation, 72
reframing, 96
rejection, 86
relaxation methods, 109, 172
religious observance, of skin, 3
remission, 91
reperfusion, abrupt, 52
repigmentation, 265
reproductive organs, 26
resistance, in acne, 188
resistance patterns, 223
rete ridges, 15
reticular layer, 16
retinoid product, application of, 186–7
retinoids, 44, 140–41
retinol, 7
rethus, 26
rhinophyma, 261
ribosomes, 12
ringworm, 237
infections, see dermatophyte infections
risk and trigger factors, of contact dermatitis, 161
rodent ulcer, 198
root, of nail, 19
rosacea, 260
erythematotelangiectatic rosacea, 260
ocular rosacea, 261
papulopustular rosacea, 260–61
phymatous rosacea, 261
treatment, 261–2
rough drying technique, 55
rubbing, 55
rule of nines, 31
sacroiliitis, 129
Salford Psoriasis Index (SPI), 99–100
salicylic acid, 197, 232
samples, 82
SAPHO, 182
Sarcoptes scabei mite, 240
scabicides, 241
scabies, 4, 222, 240, 242
scale, 32
scaling, 39, 54, 128–30, 225
scalp, 35
infections, 237
psoriasis, 125
scaling, 35
scaly lesion, 32
scar, 32
scarring, 182, 183, 230, 248
camouflage techniques, 183–4
chemical peels/dermabrasion, 184
keloid scars, steroid injections for, 184
lasers, 184
silicon sheets, 184
SCC, see squamous cell carcinoma
csclerotherapy, 262
SCORAD, 39, 159
scrapings, 234, 241
scratch–itch cycle, 56
breaking and behavioural management, 63–4
scratching, 18, 56, 86, 156
season ticket, 88
seat cushions, 57
sebaceous glands, 17, 18, 26, 179, 261
sebocytes, 180
seborrhoeic dermatitis, 157, 160, 170
seborrhoeic eczema, 151, 152
seborrhoeic keratosis, 41
sebum, 18, 24, 26, 51, 56, 60, 81, 179, 185
production, 180–81
secondy impetigo, 222
secondy lesions, 32
secondy sexual characteristics, 26
sedating antihistamines, 168
selenium sulphide, 235
self-awareness, 111
self-care, 104
self-care management, 49
self-care strategies, 60
self-care support, 104
self-cognitive theory, 109
self-efficacy, 61, 90, 107–9
self-efficacy theory, 209
self-esteem, 23
self-examination, 61, 209, 211
promotion, 209
teaching, for metastatic disease, 212
self-harm, 92
self-help groups, 207
self-management, 45, 103, 109, 172
self-management and patient support, 103–5
educational resources and strategies, 105–7
social learning theory and self-efficacy concept, 107–9
sensation, 21–3
cutaneous itch, 22
pain, 23
touch, 21–2
sensitisers, 72
sensory neuropathy, 59
sentinel lymph node biopsy (SLNB), 204, 208
septicaemia, 223, 225
serotonin, 50
serum lipid, 190
service delivery, models of, 172
service provision, 143–5
severe acne, 189
isotretinoin, 189–92
severe sunburn, 54
severity reaction, 60
sex hormones, 26
sexual abuse, 232
Sézary syndrome, 202
shame, 86
shave, 44
shea butter, 60
shear forces, 58
shingles, 44, 223, 227, 228–9
shoes, 236
signalling molecules, 20
silicon sheets, 184
skin, definition of, 1
skin barrier, 24, 29, 44, 49
disruption, 53
function, 55
skin cancer, 4, 27, 29, 195–213
causation, risk prevention and early detection, 208
attitudes and behavioural change, 208–9
epidemiology, 195–6
incidence, 195
melanoma, 202–7
non-melanoma skin lesions, 198–202
Index

skin cancer (contd.)
   nursing intervention and
   self-examination promotion, 209–13
   pre-malignant skin lesions, 196–8
   prevention, 195
   psychological impact of diagnosis, 206
   public awareness of, 196
   surgery, 207–8
Skin Care Campaign, 82
skin cleansers, 75–6
skin knowledge, 22
skin prick tests, 264
skin self-examination (SSE), 201, 209–10
socio-demographic factors, 210
   teaching for metastatic disease, 212
skin tag, 5
skin turgor, 35
skin typing, 30
sleep, 56
   disturbance, 160
   loss, 156
slippery feeling, 75
slow pain, 23
smell, 82
smoking, 123
soap, 52, 55, 59, 75, 164, 238
   physico-chemical effects of, 52
   soap substitutes, 55, 74, 75, 167
social aspects, of skin care, 85
   body image, 87
   disability and impairment, 86–7
   economic pressures, 87–8
   historical context, 85–6
   social pressures, 87
   stigma, 86
social confidence, 103
social functions, for healthy skin, 2
social impacts, 85–8
   of chronic skin conditions, 40
   of disease, 2, 85
social influences, of skin, 2
social interactions, 86
social learning theory, 61, 107–9
society, 85
socioeconomic status, 210
sodium lauryl sulphate, 52
soft cotton clothing, 56
superficial white onychomycosis (SWO), 236–7
SPF, see sun protection factor
spider naevi, 26
spondylitis, 129
spoonfuls, 78
sprays, 76
squamous cell carcinoma (SCC), 27, 196, 197, 201
diagnosis, 201
   grading, 201
   prevention, 201
   treatment, 201
staining, 136
standard battery, 42
Staphylococcal scalded skin syndrome, 224
Staphylococcus aureus, 52, 153, 154, 167, 190, 222, 223
starvation, 21
stasis eczema, 161
stem cells, 12
Stemmer’s sign, 51
steroid injections, 184
steroids, 3, 44
Stevens–Johnson syndrome, 54, 223
stigma, 86
stinging, 73
stratum basale, 12–13
stratum corneum, 14, 49, 53, 72, 80, 153
   see also horny layer
   stratum germinativum, 12–13
   stratum granulosum, 14
   stratum spinosum, 13–14
   strawberry birth marks, see arterial naevi
streptococcal throat infection, 131
Streptococcus pyogenes, 222, 223
stress, 88, 131
   management, 108
stretch marks, 27
striae atrophicae, 165
structure, of skin, 11
   appendageal structures, 17–20
   basement membrane zone, 14–15
dermis, 15–16
epidermis, 11–14
ethnic differences in, 16
subcutis, 16
subcutaneous fat, 15
subcutaneous tissues, 52
subcutis, 16
substance P, 89, 90
subungual hyperkeratosis, 256
subungal hyperkeratosis, 256
sulphalazine, 143
sulphur, 241
sun avoidance, 60
sun beds, 213
sun block, 197
sun prevention activities, 212–13
sun protection, 200, 254
sun protection factor (SPF), 212–13
   effective, 60
SunSmart, 212, 213
SunSmart campaign, 208
superantigens, 154
superficial angiomatous naevi, see arterial naevi
superficial basal cell carcinoma, 197, 199
superficial fungal skin infections, 233
superficial spreading melanoma, 203
superficial white onychomycosis (SWO), 236
supplementary prescribing, 113, 114–15
support needs, 104
surface area, of skin, 30
surface features, of skin, 29, 32
surfactants, 52
surgery, for melanoma, 207
survival, 205
swabs, 224
sweat glands, 17, 19
   apocrine sweat glands, 19–20
   eccrine sweat glands, 19
symmetric polyarthritis, 129
sympathetic nervous system, 20, 89
systemic lupus erythematosus (SLE), 251
systemic sclerosis, 251
systemic therapies, for psoriasis, 137–43
   biologics, 141–3
ciclosporin, 140
methotrexate, 139–40
nursing care, 143
phototherapy, 137
PUVA, 138–9
retinoids, 140–41
UVB, 137–8
systemic therapy, 45
systemic treatments, in children, 168
T-cell lymphoma, 258
T-cell-mediated response, 74
T-cells, 14, 123
T-helper (TH) lymphocytes, 153
T-lymphocytes, 154, 255
tacalcitol, 132
Tacrolimus (Protopic®), 168
talking therapy, 95
tars, 44, 45
tattooing, 3
technological aids, 41
   bacteriology, 42
   biopsy, 41–2
dermatoscopy, 41
mycology, 41
patch testing, 42
Wood’s light, 41
Index 285
telangiectasia, 165, 260, 262
telephone consultations, 105
telogen, 17
temperature regulation, 21
tension lines, 15
teratogenicity, of isotretinoin, 190
Terbinafine cream, 235
terbinfine, 167, 234, 236, 237
terminal hairs, 17, 24
test patch, 74
testosterone, 179
tetracycline, 187
TEWL, see transepidermal water loss
texture, of skin, 29
thusorion of planned behaviour, 61
therapeutic consultation, 111–12
therapeutic-helping relationships, features of, 111
therapeutic professional relationships, 111
therapeutic relationship, 37, 111
thermoregulation, 75
thick skin, 12
thin skin, 12
thread face-lift, 7
tickle, 22
tinea, 221, 233, 238, 242
Tinea capitis, 41, 233, 234
Tinea corporis, 233, 235
Tinea cruris, 233, 235
Tinea incognito, 238
Tinea pedis, 233, 235, 236, 237
Tinea unguium, 233, 236
tissue loading, 57
TNF inhibitors, 45
toe web intertrigo, 226
toenails, 35, 236, 237, 238
tonofilaments, 13
topical antibiotics, 187–8, 224
topical antifungals, 167
topical corticosteroids, 164–5
total emollient therapy, 75
touch, 21–2
toxic epidermal necrolysis (TEN), 44, 54, 55, 225, 253
toxic erythema, 54, 253
toxicity, of skin, 60
transepidermal water loss (TEWL), 50, 55, 72, 81
transmission, 222
treatment adherence, 109, 110, 112, 115
promotion, challenge of, 109
concordance process, importance of, 109–10
therapeutic consultation, 111–12
treatment beliefs, 105
treatment choice, 110
treatment decisions, 103–15
 treatment effectiveness, 103
treatment expectations, 109
tretinoin, 186
tribes, 3
Trichophyton, 233
Trichophyton interdigitales, 236
Trichophyton rubrum, 235, 236
Trichophyton tonsurans, 234
trichotillomania, 92
trigeminal nerve, 229
trigger factors
  in atopic eczema, 155
  in psoriasis, 130
trimethoprim, 188
trust, 111
developing, 93
Tubifast, 56
tubular bandages, 56
tumour necrosis factor α, 90
tumour thickness, 205
Type 1-mediated response, 74
Type 4-mediated response, 74
Type I receptors, 22
Type II (Ruffini corpuscles), 22
type IV hypersensitivity reaction, 42
tyrosinase, 13

U
ulcers, 32
ultraviolet light, 163
exposure, 13, 45, 131
narrow band (A and B), 44
risk behaviour, 61
unconditional positive regard, 111
United Nations Environment programme, 4
unlicensed medicines, 114
unmyelinated A fibres, 23
urea, 14, 72, 81
urinary incontinence, 50, 53
effects of, 53–4
urticaria, 45, 88, 90, 262–5
acute, 263–4
chronic, 264
investigations, 264
physical, 264
treatments, 264–5
ustekinumab, 141
UV Index, 213
UV-protective behaviour, 208
UV radiation, 4, 26, 212
UVB, 45, 137–8

V
valaciclovir, 227
varicella (chicken pox), 167, 227, 228
vaccines, 228
varicella zoster, 227–8
varicella-zoster immunoglobulin (VZIG), 228
varicella zoster virus (VZV), 227
varicose eczema, 151, 158, 161, 170, 225–6
varicose veins, 26
vascular laser, 262
vascular lesions, 29
vascular naevi, 25
vascular tracking, 44
vasculitis, 54
vasculopathy, 252
Vaseline, 71
vasoactive chemicals, 16
vasoconstriction, 21
vasodilation, 21
vector borne diseases, 4
vellus hairs, 17, 24
venous disease, 35
venous eczema, see varicose eczema
venous insufficiency, 226
venous pressure, 27
verbal persuasion, 108
vernix caseosa, 24
vesicles, 34, 162, 223, 226
vicarious experience, 108
video-assisted education, 107
video-based education, 172
violaceous, 256
viraemia, 228
viral rashes, 44
viral infections, 221, 230
hand, foot and mouth disease, 232
herpes simplex, 226–7
herpes zoster, 228–9
Kawasaki disease, 232–3
management, 167
molluscum contagiosum, 230
varicella zoster, 227–8
warts, 230–32
viral warts, 29, 167, 242
visual analogue scales, 159
vitamin A, 62, 137, 186
method of application, 137
vitamin B complex, 62
vitamin C, 61, 62
vitamin D, 23, 62, 213
vitamin D analogues, 44, 132
application method, 132–4
vitamin deficiency, 61
vitiligo, 41, 88, 90, 265–6
von Hebra, Ferdinand, 121
vulnerability of skin, 49, 53
vulvovaginitis, 238
W
warts (verrucae), 230–32
warty lesion, 32
wash product, 74
washcloth, 76
washing, of skin, 52, 53, 55
and drying practices, 55
effects of, 52–3
practices, 50, 59
water, 72
saturation, 51
Watson, R., 22
wax, 72
waxing, 17
webbing, 248
websites, 106, 114–15
wet-wrapping technique, 56, 108
white blood cells, 50
white soft paraffin, 249
whiteheads, see closed comedones
Wickham’s striae, 256
Willan, Robert, 121
Willan’s lepra, 121
Wood’s light, 41
examination, 234
wool alcohol, see lanolin
wool wax, see lanolin
worm parasites, 240
wound, 50
healing, 62, 249
wrapping technique, 56, 166
written information, 207
X
xeroderma pigmentosum, 201
xerosis, 29, 50
see also dry skin
Y
yeast infections, 238, 239
yeasts, 233
yoga, 109
Z
zinc, 62